Pulser Inc. – Apple-Simple, Google-Smart
Mission: "Fuse the best elements of medical research and mathematical analytics to win the war on human disease and suffering."
The $70 B Problem Nobody Has Fixed
  • Clinical sponsors spend US $40–70 B yearly on trials that creep phase-by-phase.
Static Trials = Snapshot Science
Traditional Clinical Data Management (CDM) relies on one-off "snapshots," manual queries, and placebo arms that halve enrollment.
Pulser turns these snapshots into movies—creating continuous data streams.
Pulser's "Self-Driving Trial" Engine
Data Stream
Continuous multi-source collection
AI Processing
Real-time analysis
Smart Design
Dynamic trial optimization
Faster Results
Accelerated conclusions
Digitized Human Intelligence
Pulser's stack deploys Hidden Markov Models, Manifold Discovery, Topology Analytics and more.
Eight provisional patents already filed.
Flywheel of Compounding Advantages
Data Moat
Every trial enlarges a federated EMR graph.
Learning Loop
Models self-improve with each pass.
Marketplace Upside
Hospitals earn revenue, sponsors gain speed, patients get therapy.
Center caption: –70% cost | –50% time.
Business Model
Pulser aims for US $50–100M ARR within 18 months.
Market > Uber's Launch TAM
Traction & 36-Month Roadmap
2024
Sandbox trial inside single hospital ✓
2025
2–4 paid adaptive trials start; seed KPIs.
2026
Library of reusable synthetic control arms.
2027
Cash-flow break-even; platform opens to CRO partners.
Technology Architecture (Secure by Design)
In-place analytics
Data never leaves HIPAA cloud
Zero-trust security
Led by CIO Dipak Reddy
GPU-backed adaptation loop
Compliant with FDA 2019 adaptive-design guidance: https://www.fda.gov/media/120711/download
Team & Advisors
Dr. Jeff Galpin MD
Founder / CEO
PI on first US gene-therapy trial
Dr. Kirstie Bellman PhD
Chief Analytics
DARPA & Aerospace AI leader
Dr. Chris Landauer PhD
Adv. Math
150+ AI papers, DoD advisor
Ken Maranga JD
Strategy/Legal
40 yrs life-science litigation
Michael Stevens PharmD
Clinical Trials
ex-VP Virology, BMS
Dipak Reddy BS CIS
CIO
20 yrs secure health-IT
Bradley Burnam
CBO
CEO, Turn Therapeutics
Dr. Brian Athey PhD
Bio-informatics
Chair, UMich CM&B
Seed / Bridge Round – US $2-4 M (mid-point US $3.5 M)
  • 47% R&D – US $1.65 M
  • 27% Payroll – US $0.95 M
  • 20% G&A – US $0.70 M
  • 6% Sales & Mktg – US $0.20 M
Runway ≈ 15 months to three paid adaptive trials.
Scale-Up Plan – Total US $10M
  • Phase 1 (Year 1) – US $3.5M foundational operations.
  • Executive & analytics salaries, GPU hardware, patents.
  • Phase 2 (Years 2-3) – ≤ US $6.5M capacity expansion & SaaS roll-out.
Financial Projections
  • Year 1 burn ≈ US $3.2M; first revenue Q4-2025.
  • Year 2 gross US $40–100M from 20 live trials.
  • Year 3-5 target US $500M+ including SaaS & equity wins.
Competitive Heat Map
Heat map shaded teal where Pulser wins on all three dimensions.
Regulatory & Industry Tailwinds
FDA Adaptive Designs Guidance (2019)
Green-lights real-time arms
VC Investment
Poured US $6.7 B into biopharma platforms Q1-2025 (DealForma). https://dealforma.com/biopharma-therapeutics-and-platforms-venture-funding-q1-2025-review/
Hospital Revenue Opportunities
Hospitals hungry for CRO-style revenue; Pulser's virtual-campus model plugs in.
The Ask & Next Steps
Seed / Bridge: US $3.5M mid-point now → validates engine & 3 paid trials.
Series A: US $6.5M follow-on to hit 20 trials & SaaS scale.
"Pulser turns drug development from a marathon into a sprint."
How to use: Drop each page into PowerPoint or Google Slides; assign suggested visuals; keep primary accent #009c9f for graphs and headers.